Alnylam Pharmaceuticals, Inc. key statistics and ratios

In fiscal 2025, Alnylam Pharmaceuticals, Inc. had return on equity of 73.3%, an operating margin of 13.5%, debt equal to 127.7% of equity and a current ratio of 2.76. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Alnylam Pharmaceuticals, Inc.: financial ratios, annual
Fiscal year	2008Dec 2008	2009Dec 2009	2010Dec 2010	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	—	—	—	—	100.0%	97.6%	88.6%	84.9%	86.4%	86.5%	85.3%	86.4%	81.8%
Operating margin	−28.9%	−47.9%	−44.1%	−900.3%	−556.2%	<−999%	−427.5%	−168.1%	−83.9%	−75.7%	−15.4%	−7.9%	13.5%
Net margin	−27.3%	−47.3%	−43.5%	−869.6%	−545.9%	<−999%	−403.2%	−174.1%	−101.0%	−109.0%	−24.1%	−12.4%	8.4%
Free-cash-flow margin	56.9%	−76.7%	−89.0%	−789.4%	−541.6%	−920.5%	−190.5%	−139.1%	−85.0%	−59.1%	2.3%	−1.9%	12.5%
Return on equity	−13.0%	−25.0%	−25.9%	−76.1%	−36.5%	−49.6%	−64.7%	−69.9%	−106.3%	—	—	—	73.3%
Return on assets	—	−9.9%	−10.0%	−49.5%	−30.1%	−42.7%	−44.6%	−29.6%	−24.2%	−31.5%	−11.9%	−6.9%	6.8%
Asset turnover	—	0.21	0.23	0.06	0.06	0.04	0.11	0.17	0.24	0.29	0.50	0.56	0.81
Current ratio	—	2.65	2.49	5.10	12.23	6.69	4.87	4.47	4.04	3.51	3.08	2.78	2.76
Debt to equity	0.0%	0.0%	0.0%	16.3%	1.7%	2.3%	0.0%	18.8%	114.9%	—	—	>999%	127.7%
Interest cover (operating income ÷ interest)	n/m	—	—	—	—	—	—	n/m	n/m	n/m	n/m	n/m	2.0x
Effective tax rate	—	—	—	—	—	—	—	—	—	—	—	—	2.9%
R&D as % of revenue	100.7%	108.2%	106.3%	810.9%	434.5%	674.7%	298.1%	132.9%	93.8%	85.1%	54.9%	50.1%	35.5%
SG&A as % of revenue	—	—	—	189.5%	221.7%	510.4%	218.0%	119.4%	73.5%	74.3%	43.5%	43.4%	32.6%
Capital spending as % of revenue	11.2%	4.9%	4.7%	136.9%	115.9%	169.4%	63.8%	14.3%	9.0%	6.9%	3.4%	1.5%	1.6%
Free cash flow ÷ net income	—	—	—	—	—	—	—	—	—	—	—	—	148.3%

US$ thousands unless shown otherwise. Fiscal quarters.

Alnylam Pharmaceuticals, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	83.6%	82.7%	88.2%	81.6%	84.2%	75.6%	76.9%	75.2%
Operating margin	−15.4%	−17.7%	3.0%	−2.1%	29.5%	12.0%	17.9%	23.7%
Net margin	−22.3%	−14.1%	−3.1%	−9.3%	23.4%	10.2%	12.7%	148.6%
Free-cash-flow margin	7.9%	−17.5%	−21.4%	14.7%	22.8%	17.7%	—	18.6%
Current ratio	2.75	2.78	3.04	2.80	2.54	2.76	3.05	2.48
R&D as % of revenue	54.1%	50.6%	44.6%	41.8%	28.7%	33.9%	32.0%	28.0%
SG&A as % of revenue	44.1%	49.8%	40.4%	41.8%	25.8%	29.7%	27.0%	23.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · September 30, 2026

What it owns · $8.0bn

Short-term assets $5.1bnLonger-term assets $2.9bn

What it owes, and who funded it · $8.0bn

Short-term liabilities $2.1bnLonger-term liabilities $2.3bnShareholders' equity $3.6bn

Short-term assets cover short-term liabilities $5.1bn of assets due within a year against $2.1bn of liabilities due within a year.
Short-term assets cover long-term liabilities $5.1bn short-term assets against $2.3bn of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Alnylam Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

33 /100

Weak moat

How hard Alnylam Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 5 / 20

Cash operating profit has been a median 5.0% of total assets over 7 years.
Pricing power 20 / 20

Gross margin has been a median 86.4%, moving by 1.9 percentage points (standard deviation) across 7 years.
Durability 10 / 20

Operating margin has been a median -79.8%; its worst year was -1087.6%.
Cash conversion 2 / 20

Free cash flow was positive in 2 of 10 years, at a median -82.7% of revenue.
Discipline 1 / 20

The diluted share count rose 17.1% over five years; stock-based pay has been a median 20.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (38 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ALNY vs NBIX ALNY vs BMRN ALNY vs ARGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alnylam Pharmaceuticals, Inc.